Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ.

ABSTRACT:

Background

Imeglimin is a new anti-diabetic drug which promotes insulin secretion from pancreatic β-cells and reduces insulin resistance in insulin target tissues. However, there have been no reports examining the possible anti-atherosclerotic effects of imeglimin. In this study, we investigated the possible anti-atherosclerotic effects of imeglimin using atherosclerosis model ApoE KO mice treated with streptozotocin (STZ).

Methods

ApoE KO mice were divided into three groups: the first group was a normoglycemic group without injecting STZ (non-DM group, n = 10). In the second group, mice were injected with STZ and treated with 0.5% carboxymethyl cellulose (CMC) (control group, n = 12). In the third group, mice were injected with STZ and treated with imeglimin (200 mg/kg, twi

SUBMITTER: Sanada J 

PROVIDER: S-EPMC10953273 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature